Premenstrual syndrome (PMS) can produce physical and emotional or behavioral symptoms in the days before menstruation.
Physical symptoms of PMS may include:
Emotional and behavioral symptoms of PMS may include:
Premenstrual dysphoric disorder (PMDD) is a specific psychiatric condition marked by severe depression, irritability, and tension before menstruation. For a doctor to confirm a diagnosis of PMDD, a woman must have symptoms during the last week of the premenstrual phase and improve within a few days after menstruation starts.
Five or more of the following symptoms must occur:
Premenstrual syndrome (PMS) is a set of emotional and physical symptoms that typically occur about 5 days before a woman starts her monthly menstrual cycle. The symptoms usually stop when menstruation begins, or shortly thereafter.
A menstrual cycle lasts an average of 28 days, although the cycle length may range from 21 to 34 days and still be considered normal. When a woman reaches her 40s the cycle lengthens, reaching an average of 31 days by age 49.
Ovulation is when an egg is released from the woman's ovary, which occurs mid-way through the menstrual cycle, around day 14 (in a 28-day cycle). A menstrual cycle is associated with hormonal changes and has two main phases, which precede and follow ovulation:
PMS is associated with the luteal phase of the menstrual cycle, after ovulation. Estrogen and progesterone levels rise in the first part of the luteal phase to help prepare the endometrial lining of the uterus for an embryo.
If conception (pregnancy) does not occur, the levels of these hormones decrease in the latter part of the luteal phase, and the lining and unfertilized egg are shed through menstruation in the beginning of the follicular phase. Levels of other types of hormones also rise and fall during the menstrual cycle.
Premenstrual dysphoric disorder (PMDD) is a condition marked by severe depression symptoms, irritability, and tension before menstruation. The symptoms of PMDD are similar to those of PMS, but they are generally more severe and debilitating. Like PMS, symptoms of PMDD occur during the luteal phase in the week before menstrual bleeding begins. Symptoms usually improve within a few days after the period starts.
Typical Menstrual Cycle
Typical No. of Days
Follicular (Proliferative) Phase
Cycle Days 1 to 6: Beginning of menstruation to end of blood flow.
Estrogen and progesterone start out at their lowest levels.
Follicle-stimulating hormone (FSH) levels rise to stimulate maturity of follicles. Ovaries start producing estrogen and levels rise, while progesterone remains low.
Cycle Days 7 to 13: The endometrium (the inner lining of the uterus) thickens to prepare for the egg implantation.
Cycle Day 14:
Surge in luteinizing hormone (LH). Largest follicle bursts and releases egg into fallopian tube.
Luteal (Secretory) Phase, also known as the Premenstrual Phase
Cycle Days 15 to 28:
Ruptured follicle develops into corpus luteum, which produces progesterone. Progesterone and estrogen stimulate blanket of blood vessels to prepare for egg implantation.
If fertilization occurs:
Fertilized egg attaches to blanket of blood vessels that supplies nutrients for the developing placenta. Corpus luteum continues to produce estrogen and progesterone.
If fertilization does not occur:
Corpus luteum deteriorates. Estrogen and progesterone levels drop. The blood vessel lining sloughs off and menstruation begins.
Doctors do not know exactly what causes PMS. Fluctuations in female reproductive hormones (progesterone or estrogen) and brain chemicals may play a role although their exact significance is unclear. Hormonal levels seem to be the same in women whether or not they have PMS. It is possible that women with PMS are somehow more sensitive to these changing levels of hormones.
Disruptions in the hypothalamic-pituitary-adrenal (HPA) system may be involved with PMS and premenstrual dysphoric disorder (PMDD). The HPA system controls reproduction, appetite, and feelings of well-being, and is also involved in regulating the stress response. A number of hormones and neurotransmitters (chemical messengers in the brain) play important and complicated interrelated roles in the activity of the HPA system:
While hormonal and brain chemical changes certainly play a role, it is not exactly clear how they cause PMS or PMDD. Cyclic fluctuations in some of these hormones, and not whether their levels are high or low, may be the important factors in premenstrual problems.
Many women in their reproductive years experience some of the emotional and physical symptoms of premenstrual syndrome (PMS). A small percentage of women report very severe symptoms, notably premenstrual dysphoric disorder (PMDD). A number of factors may put a woman at higher risk for PMS.
PMS tends to occurs in women who are in their late 20s to early 40s. Symptoms usually begin when a woman is in her mid-twenties. PMS and other menstrual problems end at menopause when a woman stops having menstrual periods.
A woman whose mother had PMS is more likely to have PMS herself.
Women with past or current mood or anxiety disorders, including depression, may be at increased risk for PMS and PMDD. A history of postpartum depression is a risk factor as is history of alcohol abuse.
Poor eating habits may contribute to PMS. Dietary issues associated with PMS include:
Stress does not cause PMS, but it may worsen symptoms. Exercise can help reduce stress and boost energy levels.
Depression and PMS often coincide, and may in some cases be due to common factors. Some studies suggest that PMDD may increase the risk of depression after giving birth (postpartum) or during the transition to menopause (perimenopause).
A number of conditions worsen during the premenstrual or menstrual phase of the cycle, a phenomenon sometimes referred to as menstrual magnification.
About half of women with migraines report an association with menstruation, usually in the first days before or after menstruation begins. Compared to migraines that occur at other times of the month, menstrual migraines are often more severe, last longer, and do not have auras.
Asthma attacks often increase or worsen during the premenstrual period.
Many other chronic medical conditions may be exacerbated during the premenstrual phase, including epilepsy and other seizure disorders, multiple sclerosis, systemic lupus erythematosus, irritable bowel syndrome, and inflammatory bowel diseases such as Crohn and ulcerative colitis.
PMS is a set of physical, emotional, and behavioral symptoms that occur during the last week of the luteal phase (1 to 2 weeks before menstruation). The symptoms typically start in the 5 days before menstruation begins and go away within 4 days after bleeding starts. Symptoms do not start again until at least day 13 in the cycle.
Once established, the symptoms tend to remain fairly constant until menopause, although they can vary from cycle to cycle.
The American Psychiatric Association has specific criteria that define premenstrual dysphoric disorder (PMDD). PMDD is a condition marked by severe depression, irritability, and tension before menstruation. PMDD has features of both anxiety and depression disorders.
Symptoms must occur during the last week of the premenstrual (luteal) phase in most menstrual cycles. They should improve within a few days after the period starts. Symptoms should be absent by the end of the first menstrual week. They should markedly interfere with work or social functioning. Also, symptoms should not just be those of another underlying disorder.
Five or more of the following symptoms must occur:
Your health care provider will ask about your symptoms and may ask you to fill out a questionnaire. The best method for determining your PMS patterns is to track your symptoms for 2 to 3 months:
If the symptoms consistently resolve once menstruation begins, they are most likely caused by hormonal fluctuations. If they persist or do not appear to be associated with a regular cycle, other conditions may be causing them. Among the possible conditions that mimic some PMS symptoms are:
For many women, PMS symptoms can be relieved by lifestyle changes (food modifications, exercise, and possibly vitamin B-6 and calcium supplements).
Women with more severe PMS whose symptoms have not been helped by lifestyle changes should discuss drug treatment options with their doctors. Medications for PMS include:
Cognitive-behavioral psychotherapy may be an appropriate alternative to antidepressants for some women.
A healthy lifestyle, including regular exercise and a healthy diet, is the first step towards managing PMS. For many women with mild symptoms, lifestyle approaches are sufficient to control symptoms.
Women should follow the general guidelines for a healthy diet. These guidelines include eating plenty of whole grains and fresh fruits and vegetables and avoiding saturated fats and commercial junk foods. Making dietary adjustments starting about 14 days before a period may help control premenstrual symptoms:
Some evidence indicates that calcium, and other minerals and vitamins, may help with PMS symptoms.
Calcium has the most evidence as an effective dietary treatment for PMS. The recommended dietary intake for women is 1,000 mg/day before age 50 and 1,200 mg/day after age 50. Calcium-rich foods include dairy products, dark green vegetables, nuts, grains, beans, and canned salmon and sardines. Food sources provide the most nutritional value, but supplements may be helpful for certain women.
Limited clinical evidence suggests that vitamin B6 may help reduce PMS symptoms. Typically, women take 100 mg/day. Very high doses (500 to 2,000 mg daily over long periods) can cause nerve damage with symptoms of numbness in the feet and hands.
Food sources of B6 include meats, oily fish, poultry, whole grains, dried fortified cereals, soybeans, avocados, baked potatoes with skins, watermelon, plantains, bananas, peanuts, and brewer's yeast. Women prone to Candida vaginitis (yeast infections) should not increase their intake of dietary yeast.
Other B Vitamins
Other B vitamins that may play a role in PMS include riboflavin (B2), niacin (B3), and folate (folic acid). Food sources for these vitamins include:
The effects of magnesium are not as well established as with calcium, but some evidence suggests that it may be helpful in reducing fluid retention in women with mild PMS. Causes of magnesium deficiencies include excessive alcohol, salt, soda, and coffee intake, as well as profuse sweating, intense stress, and heavy menstrual bleeding. Magnesium can be toxic in high amounts and can interact with certain drugs. Discuss with your doctor whether you should take a magnesium supplement.
Some research suggests that women who consume a diet high in plant-based (non-heme) iron have a lower risk for PMS symptoms. Dietary sources of plant-based iron include lentils, beans, spinach, and iron-fortified cereal. Plant-based iron is also available in supplement form, but it is important not to consume more than 45 mg/day.
Exercise, especially aerobic exercise, increases natural opioids in the brain (endorphins) and improves mood. Exercise is also very important for maintaining good physical health. Even moderate exercise, such as taking a 30-minute walk every day, is beneficial. Although not an aerobic exercise, yoga releases muscle tension, regulates breathing, and reduces stress. Relaxation techniques, including meditation, can also help reduce stress.
Physical activity contributes to health by reducing the heart rate, decreasing the risk for cardiovascular disease, and reducing the amount of bone loss that is associated with age and osteoporosis. Physical activity also helps the body use calories more efficiently, thereby helping in weight loss and maintenance. It can also increase basal metabolic rate, reduce appetite, and help reduce body fat.
Many women with PMS suffer from sleep problems, either sleeping too much or too little. Achieving better sleep habits may help relieve symptoms.
Generally, manufacturers of herbal remedies and dietary supplements do not need approval from the Food and Drug Administration (FDA) to sell their products. Just like a drug, herbs and supplements can affect the body's chemistry, and therefore have the potential to produce side effects that may be harmful. There have been a number of reported cases of serious and even lethal side effects from herbal products. Always check with your doctor before using any herbal remedies or dietary supplements.
A number of herbal remedies are used for PMS symptoms. With a few exceptions, studies have not found any herbal or dietary supplement remedy to be any more effective than placebo for relieving PMS symptoms.
Chasteberry (Vitex agnus castus) is a traditional herbal remedy for many gynecological conditions. Some small studies have indicated it may be helpful for PMS symptoms, including breast discomfort. However, the evidence is not strong.
Evening Primrose Oil
Some women find that taking evening primrose oil helps improve PMS and symptoms such as breast tenderness. However, several rigorous studies have reported no benefit.
Ginger Tea. Ginger tea is safe and may help soothe mild nausea and other minor symptoms of PMS.
The following are special concerns for people taking natural remedies for PMS:
Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs block prostaglandins, substances that cause inflammation. NSAIDs are usually among the first drugs recommended for almost any kind of minor pain.
The most common NSAIDs used for PMS are nonprescription ibuprofen (Advil, Motrin, Midol, and generic) and naproxen (Aleve, generic) or prescription mefenamic acid (Postel, generic). NSAIDs are most helpful when started 7 days before menstruation and continued for 4 days into the cycle. Long-term daily use of any NSAID can increase the risk for gastrointestinal bleeding and ulcers.
Acetaminophen (Tylenol, generic) is a good alternative to NSAIDs, especially when stomach problems, ulcers, or allergic reactions prohibit their use. Products that combine acetaminophen with other drugs that reduce PMS symptoms may be helpful. Brands include Pamprin and Premsyn, which are also available as generic medication. Such drugs typically include a diuretic to reduce fluid retention and an antihistamine to relieve irritability.
Selective Serotonin-Reuptake Inhibitors (SSRIs)
SSRIs are the main type of antidepressants used to treat PMDD and severe PMS mood symptoms.
In the United States, three SSRIs are approved by the FDA for the treatment of PMDD:
Other SSRIs sometimes prescribed for PMDD include citalopram (Celexa, generic) and escitalopram (Lexapro, generic). The serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine (Effexor, generic) has also shown benefit in some studies.
SSRIs appear to work much faster for relieving PMS-related depression than when used to treat major depression. These drugs are typically prescribed with either continuous (daily) dosing throughout the month or an intermittent dosing regimen. With intermittent dosing, women take the antidepressant during the 14-day premenstrual period of their luteal phase.
General side effects of SSRIs may include nausea, drowsiness, headache, weight gain and sexual dysfunction. Antidepressants may increase the risk for suicidal thinking and behavior in young adults ages 18 to 24. This risk for "suicidality" generally occurs during the first few months of treatment.
Anti-anxiety drugs (called anxiolytics) may be helpful for women with severe premenstrual anxiety that is not relieved by SSRIs or other treatments.
Alprazolam (Xanax) is a benzodiazepine anxiolytic often prescribed for PMS. However, benzodiazepines can have serious side effects. Dependence is a risk and can occur after as short a time as 3 months of use. Using alprazolam for only a few days per month when symptoms are most severe reduces this risk.
Common side effects include daytime drowsiness and a hung-over feeling. Respiratory problems may be worsened. Benzodiazepines also increase appetite, particularly for fats. Overdose is very serious, although rarely fatal. Benzodiazepines are potentially dangerous when used in combination with alcohol.
Buspirone (BuSpar, generic) is a drug used to treat anxiety. It may help reduce premenstrual irritability. Unlike benzodiazepines, buspirone is not addictive. Buspirone also seems to have less pronounced side effects than benzodiazepines and no withdrawal effects, even when the drug is discontinued quickly. Common side effects include dizziness, drowsiness, and nausea.
Hormone therapies are used to interrupt the hormonal cycle that triggers PMS symptoms. One method to accomplish this is through birth control pills.
Birth Control Pills
Oral contraceptives (OCs) contain combinations of an estrogen (usually estradiol) and a progestin (the synthetic form of progesterone).
The birth control pill Yaz is approved specifically for treatment of premenstrual dysmorphic disorder (PMDD). A related birth control pill, Beyaz, which is supplemented with the B vitamin folate, is also approved for treatment of PMDD. Both of these pills contain a newer type of progestin called drospirenone.
The FDA warns that birth control pills that contain drospirenone may increase the risk for blood clots much more than the progestin levonorgestrel contained in other types of birth control pills. Some studies have indicated that the risk for blood clots is 3 times higher with drospirenone.
Because of the high risk for blood clots, stroke, and heart attack, Yaz and Beyaz should not be used by women who are over age 35 or by those who smoke. In addition, Yaz and Beyaz should not be used by women with kidney, liver, or adrenal disease. Drospirenone is related to spironolactone, a diuretic, and can increase potassium levels.
Some women with PMS use extended-cycle (continuous-dosing) OCs to reduce or eliminate their monthly periods:
Side effects of OCs include nausea, breakthrough bleeding, breast tenderness, headache (which may worsen in smokers or women with a history of migraine), and weight gain. Women who are over age 35 and smoke, or who are at risk for blood clots, heart attack, or stroke, should not take combination birth control pills. Some women may experience worsening of PMS symptoms with OCs.
Gonadotropin-releasing hormone (GnRH) agonists (also called analogs) are powerful hormonal drugs that suppress ovulation and, thereby, the hormonal fluctuations that produce PMS. They are sometimes used for very severe PMS symptoms and to improve breast tenderness, fatigue, and irritability. GnRH analogs appear to have little effect on depression.
GnRH agonists include the implant goserelin (Zoladex), a monthly injection of leuprolide (Lupron, Depot, generic), and the nasal spray nafarelin (Synarel).
Common side effects (which can be severe in some women) include menopausal-like symptoms such as hot flashes, night sweat, weight change, and depression. The side effects vary in intensity, depending on the particular GnRH agonist. The most important concern is possible osteoporosis from estrogen loss. Doctors recommend that women not take these drugs for more than 6 months.
Danazol (Danocrine, generic) is a synthetic substance that resembles male hormones. It has very severe side effects and is used only if other therapies fail. It suppresses estrogen and menstruation and is used in low doses for severe PMS and premenstrual migraines. Side effects include masculinizing effects such as facial hair growth, deepening of the voice, and acne.
Diuretics are drugs that increase urination and help eliminate water and salt from the body. They reduce bloating and breast tenderness in women with PMS. Diuretics can have considerable side effects and should not be used for mild or moderate PMS symptoms. Spironolactone (Aldactone, generic) is the most commonly prescribed diuretic for PMS.
Spironolactone can increase potassium levels in the body. Women should be sure not to take additional potassium if they are taking spironolactone, and people with kidney disease should avoid this medication. Diuretics interact with a number of other drugs, including certain antidepressants. Women who are considering diuretics should let their doctors know of any other drugs or supplements that they are taking.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5). Arlington, VA: American Psychiatric Association; 2013.
Biggs WS, Demuth RH. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2011 Oct 15;84(8):918-24. PMID: 22010771 www.ncbi.nlm.nih.gov/pubmed/22010771.
Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 May;45(5):1545-88. Epub 2014 Feb 6. PMID: 24503673 www.ncbi.nlm.nih.gov/pubmed/24503673.
Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Intake of selected minerals and risk of premenstrual syndrome. Am J Epidemiol. 2013 May 15;177(10):1118-27. Epub 2013 Feb 26. PMID: 23444100 www.ncbi.nlm.nih.gov/pubmed/23444100.
Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr. 2011 May;93(5):1080-6. Epub 2011 Feb 23. PMID: 21346091 www.ncbi.nlm.nih.gov/pubmed/21346091.
Ferri FF. Premenstrual syndrome. In: Ferri FF, ed. Ferri's Clinical Advisor 2016. Philadelphia, PA: Elsevier; 2016:1008-9.
Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011 Apr 21;342:d2151. PMID: 21511805 www.ncbi.nlm.nih.gov/pubmed/21511805
Lentz GM. Primary and secondary dysmenorrheal, premenstrual syndrome, and premenstrual dysphoric disorder. Etiology, diagnosis, management. In: Katz VL, Lobo RA, Lentz G, et al., eds. Comprehensive Gynecology. 6th ed. St. Louis, MO: Elsevier Mosby; 2012:chap 36.
Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012 Feb 15;2:CD006586. PMID: 22336820 www.ncbi.nlm.nih.gov/pubmed/22336820.
Marjoribanks J, Brown J, O'Brien PM, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013 Jun 7;6:CD001396. PMID: 23744611 www.ncbi.nlm.nih.gov/pubmed/23744611.
[No authors listed] ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol. 2010 Jan;115(1):206-18. PMID: 20027071 www.ncbi.nlm.nih.gov/pubmed/20027071.
Parkin L, Sharples K, Hernandez RK, et al. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011 Apr 21;342:d2139. PMID: 21511804 www.ncbi.nlm.nih.gov/pubmed/21511804.
Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. Am J Obstet Gynecol. 2010 Mar;202(3):221-31. PMID: 20207238 www.ncbi.nlm.nih.gov/pubmed/20207238
Roach RE, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015 Aug 27;8:CD011054. PMID: 26310586 www.ncbi.nlm.nih.gov/pubmed/26310586.
Sylvén SM, Ekselius L, Sundström-Poromaa I, et al. Premenstrual syndrome and dysphoric disorder as risk factors for postpartum depression. Acta Obstet Gynecol Scand. 2013 Feb;92(2):178-84. Epub 2012 Dec 14. PMID: 23157487 www.ncbi.nlm.nih.gov/pubmed/23157487.
Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10. PMID: 18395582 www.ncbi.nlm.nih.gov/pubmed/18395582.
Reviewed By: Irina Burd, MD, PhD, Associate Professor of Gynecology and Obstetrics at Johns Hopkins University School of Medicine, Baltimore, MD. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.